Want to see SE:PILA full AI Analyst Report?

PILA PHARMA AB (PILA) Price & Analysis

1 Followers

PILA Stock Chart & Stats

kr2.20

-kr0.50(-13.33%)

At close: Mar 06 4:00 PM EST

kr2.20

-kr0.50(-13.33%)

Day’s Range― - ―

52-Week Rangekr1.02 - kr3.87

Previous CloseN/A

Volume9.62K

Average Volume (3M)235.52K

Market Cap

kr60.76M

Enterprise Valuekr46.23M

Total Cash (Recent Filing)kr15.90M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Aug 27, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding45,682,120

10 Day Avg. Volume194,482

30 Day Avg. Volume235,519

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet HealthThe company carries no recorded debt and materially increased equity in 2025, which reduces insolvency risk and preserves financial optionality. For a loss-making biotech, a clean leverage profile and stronger equity base extend runway and improve ability to raise non-dilutive or staged financing when needed.

Revenue ReboundAfter prior declines, revenue grew in 2025 indicating some recovery in underlying activity or partnerships. For an R&D-focused biotech, persistent top-line growth, even from a low base, signals strengthening validation of programs or milestone receipts that can support continued development and reduce reliance on pure equity raises.

Focused R&D PipelineA clear therapeutic focus on TRPA1 for metabolic diseases gives the company a differentiated scientific niche. Concentrated R&D around a defined mechanism and lead candidate can attract targeted partnerships, grant funding, or licensing deals, providing strategic options beyond pure equity financing over the medium term.

Bears Say

Persistent LossesOperating losses have increased materially, reflecting ongoing high R&D and operating spend without offsetting commercial revenue. Continued widening losses erode equity over time, increase fundraising needs, and create execution risk if capital markets or partners become less accessible in 2–6 months.

Weak Cash GenerationConsistent negative operating and free cash flow indicate ongoing cash burn that necessitates external funding. Reliance on new financing or partner milestones creates dilution and execution risk; without sustainable cash generation the firm may face constrained R&D progress or slowdowns in pipeline advancement.

Small, Volatile Revenue BaseRevenues remain small and inconsistent, with negative margins across years, showing limited commercial traction or scalable income. This weak revenue base prevents internal funding of development, reduces bargaining power with partners, and leaves program continuity exposed to funding cycles and milestone timing.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.87 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr60.76M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -kr0.369 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.369.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate is -0.22.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -kr0.369 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.83%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.